In our lung cancer quiz, you'll get a chance to test your knowledge of the management of sarcopenia in patients with lung cancer.
Atezolizumab monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment in patients with wild-type non–small cell lung cancer with PD-L1 expressio...
MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.
Proton therapy’s direct and precise application of radiation for mid-stage lung cancer is being investigated in an ongoing phase III trial at the University of Cincinnati.
About a fifth of patients with lung cancer in the United States receive no treatment at all, while approximately 6 in 10 receive the minimal treatments recommended by the National Comprehensive C...
The probiotics and prebiotics of yogurt and fiber consumption is associated with decreased risk of lung cancer.
A compound called MRTX849 is showing signs of being the first effective inhibitor of the KRAS G12C-mutant subtype of non-small cell lung and colorectal cancers.
A look at the latest lung cancer research, recent advances in the field and their clinical applications.
Pembrolizumab offers survival advantages at a much lower cost over atezolizumab.
A liquid biopsy may be able to predict the efficacy of EGFR-targeted tyrosine kinase inhibitors in patients with non–small cell lung cancer.
A pooled analysis of safety, efficacy of pembrolizumab in patients 75+ years of age with PD-L1+ NSCLC
The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.
The agent has a high affinity and specificity for interleukin-1 beta.
Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.
Sequential afatinib and osimertinib improved median overall survival by almost 3.5 years in patients with EGFR T790M-positive non-small cell lung cancer, with an even greater benefit seen in thos...